Jones Lang LaSalle Inc vs Eli Lilly And Co — how do they compare? Jones Lang LaSalle Inc trades at $361.02 (market cap $16.72B), while Eli Lilly And Co trades at $1,212.8 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 64.6× Jones Lang LaSalle Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | LLY | |
|---|---|---|
Market Cap | $16.72B | $1.08T |
Sector | Real Estate | Health |
52-Week High | $373.24 | $1.24K |
52-Week Low | $280.16 | $639.43 |
Enterprise Value | $19.48B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →